Literature DB >> 26048148

Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate γδ-Low T Cells.

Yasutomo Imai1, Natarajan Ayithan2, Xuesong Wu1, Ying Yuan2, Li Wang3, Sam T Hwang4.   

Abstract

Programmed cell death 1 (PD-1) is a key regulatory molecule that has been targeted in human cancers, including melanoma. In clinical testing, Abs against PD-1 have resulted in psoriasiform dermatitis (PsD). To determine whether PD-1 regulates PsD, we compared skin responses of PD-1-deficient (PD-1KO) mice and wild-type (WT) controls in an imiquimod (IMQ)-induced murine model of psoriasis. PD-1KO mice showed severe epidermal hyperplasia, greater neutrophilic infiltration, and higher expression of Th17 cytokines (versus WT mice). IMQ exposure increased PD-1 expression by skin γδ-low (GDL) T cells and enhanced expression of PD-L1 by keratinocytes. Three-fold increases in the percentage of IL-17A(+) GDL T cells were observed in skin cell suspensions derived from IMQ-treated PD-1KO mice (versus WT controls), suggesting that the lack of PD-1 has a functional effect not only on αβ T cells, but also on GDL T cells, and that PD-1 may play a regulatory role in PsD.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26048148      PMCID: PMC4490979          DOI: 10.4049/jimmunol.1500448

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing γδ T cells.

Authors:  Ryutaro Yoshiki; Kenji Kabashima; Tetsuya Honda; Satoshi Nakamizo; Yu Sawada; Kazunari Sugita; Haruna Yoshioka; Shun Ohmori; Bernard Malissen; Yoshiki Tokura; Motonobu Nakamura
Journal:  J Invest Dermatol       Date:  2014-02-25       Impact factor: 8.551

2.  IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice.

Authors:  Astrid B Van Belle; Magali de Heusch; Muriel M Lemaire; Emilie Hendrickx; Guy Warnier; Kyri Dunussi-Joannopoulos; Lynette A Fouser; Jean-Christophe Renauld; Laure Dumoutier
Journal:  J Immunol       Date:  2011-11-30       Impact factor: 5.422

Review 3.  Programmed death-1 pathway in cancer and autoimmunity.

Authors:  Ariel Pedoeem; Inbar Azoulay-Alfaguter; Marianne Strazza; Gregg J Silverman; Adam Mor
Journal:  Clin Immunol       Date:  2014-04-26       Impact factor: 3.969

4.  Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses.

Authors:  Fumihiko Tsushima; Hideyuki Iwai; Noriko Otsuki; Masaaki Abe; Sachiko Hirose; Tomohide Yamazaki; Hisaya Akiba; Hideo Yagita; Yuzo Takahashi; Ken Omura; Ko Okumura; Miyuki Azuma
Journal:  Eur J Immunol       Date:  2003-10       Impact factor: 5.532

5.  A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis.

Authors:  Cynthia Helms; Li Cao; James G Krueger; Ellen M Wijsman; Francesca Chamian; Derek Gordon; Michael Heffernan; Jil A Wright Daw; Jason Robarge; Jurg Ott; Pui-Yan Kwok; Alan Menter; Anne M Bowcock
Journal:  Nat Genet       Date:  2003-11-09       Impact factor: 38.330

6.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

7.  Interplay between CXCR2 and BLT1 facilitates neutrophil infiltration and resultant keratinocyte activation in a murine model of imiquimod-induced psoriasis.

Authors:  Hayakazu Sumida; Keisuke Yanagida; Yoshihiro Kita; Jun Abe; Kouji Matsushima; Motonao Nakamura; Satoshi Ishii; Shinichi Sato; Takao Shimizu
Journal:  J Immunol       Date:  2014-03-24       Impact factor: 5.422

8.  CCR6 is required for epidermal trafficking of γδ-T cells in an IL-23-induced model of psoriasiform dermatitis.

Authors:  Tomotaka Mabuchi; Tej Pratap Singh; Tomonori Takekoshi; Guang-Fu Jia; Xuesong Wu; Mandy C Kao; Ido Weiss; Joshua M Farber; Sam T Hwang
Journal:  J Invest Dermatol       Date:  2012-08-16       Impact factor: 8.551

9.  Deficiency in IL-17-committed Vγ4(+) γδ T cells in a spontaneous Sox13-mutant CD45.1(+) congenic mouse substrain provides protection from dermatitis.

Authors:  Elizabeth E Gray; Francisco Ramírez-Valle; Ying Xu; Shuang Wu; Zhihao Wu; Klaus E Karjalainen; Jason G Cyster
Journal:  Nat Immunol       Date:  2013-04-28       Impact factor: 25.606

10.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.

Authors:  Giao Q Phan; James C Yang; Richard M Sherry; Patrick Hwu; Suzanne L Topalian; Douglas J Schwartzentruber; Nicholas P Restifo; Leah R Haworth; Claudia A Seipp; Linda J Freezer; Kathleen E Morton; Sharon A Mavroukakis; Paul H Duray; Seth M Steinberg; James P Allison; Thomas A Davis; Steven A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 12.779

View more
  21 in total

Review 1.  IL-17+ γδ T cells as kick-starters of inflammation.

Authors:  Pedro H Papotto; Julie C Ribot; Bruno Silva-Santos
Journal:  Nat Immunol       Date:  2017-05-18       Impact factor: 25.606

Review 2.  The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis.

Authors:  Neha Shah; Sabina Sandigursky; Adam Mor
Journal:  Bull Hosp Jt Dis (2013)       Date:  2017-05

3.  Diet-induced obesity exacerbates imiquimod-mediated psoriasiform dermatitis in anti-PD-1 antibody-treated mice: Implications for patients being treated with checkpoint inhibitors for cancer.

Authors:  Sebastian Yu; Xuesong Wu; Zhenrui Shi; Mindy Huynh; Prasant Kumar Jena; Lili Sheng; Yan Zhou; Dan Han; Yu-Jui Yvonne Wan; Samuel T Hwang
Journal:  J Dermatol Sci       Date:  2020-01-24       Impact factor: 4.563

Review 4.  γδ T cells in rheumatic diseases: from fundamental mechanisms to autoimmunity.

Authors:  Cuong Thach Nguyen; Emanual Maverakis; Matthias Eberl; Iannis E Adamopoulos
Journal:  Semin Immunopathol       Date:  2019-09-10       Impact factor: 9.623

Review 5.  Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.

Authors:  Chieh-Hsun Chen; Hsin-Su Yu; Sebastian Yu
Journal:  Curr Oncol       Date:  2022-04-18       Impact factor: 3.109

6.  Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis.

Authors:  Na Li; Wenwen Xu; Ying Yuan; Natarajan Ayithan; Yasutomo Imai; Xuesong Wu; Halli Miller; Michael Olson; Yunfeng Feng; Yina H Huang; Mary Jo Turk; Samuel T Hwang; Subramaniam Malarkannan; Li Wang
Journal:  Sci Rep       Date:  2017-05-03       Impact factor: 4.379

7.  Anti-Programmed Cell Death-1-Induced Plaque and Guttate Psoriasis.

Authors:  Toshiyuki Yamamoto
Journal:  Indian J Dermatol       Date:  2018 Jan-Feb       Impact factor: 1.494

8.  Suppressed Programmed Death 1 Expression on CD4+ and CD8+ T Cells in Psoriatic Patients.

Authors:  Joanna Bartosińska; Ewelina Zakrzewska; Dorota Raczkiewicz; Joanna Purkot; Anna Michalak-Stoma; Małgorzata Kowal; Dorota Krasowska; Grażyna Chodorowska; Krzysztof Giannopoulos
Journal:  Mediators Inflamm       Date:  2017-10-17       Impact factor: 4.711

9.  IL-23-induced macrophage polarization and its pathological roles in mice with imiquimod-induced psoriasis.

Authors:  Yuzhu Hou; Linnan Zhu; Hongling Tian; Hai-Xi Sun; Ruoyu Wang; Lianfeng Zhang; Yong Zhao
Journal:  Protein Cell       Date:  2018-03-05       Impact factor: 14.870

10.  PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin.

Authors:  Xiao Miao; Rong Xu; Bin Fan; Jie Chen; Xin Li; Weiwei Mao; Shengyuan Hua; Bin Li
Journal:  Sci Rep       Date:  2018-01-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.